Study Evaluating the Safety and Efficacy of Bazedoxifene in Postmenopausal Asian Women
Phase 3
Completed
- Conditions
- PostmenopauseOsteoporosis
- Registration Number
- NCT00384072
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to evaluate the effect of 20 mg of bazedoxifene in comparison to placebo on bone mineral density after 6 months of therapy in a population of postmenopausal Asian women.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 500
Inclusion Criteria
-
Generally healthy Asian women 45 years of age or older who are at least 1 year postmenopausal
-
Subjects must qualify for one of the following categories (a or b):
- Greater than 1 year but less than 5 years postmenopausal with at least one of the ospeoporosis risk factors
- Equal or greater than 5 years postmenopausal with BMD T-score at lumbar spine or femoral neck between -1 and -2.5 (values of -1 and -2.5 are acceptable) with at least one osteoporosis risk factor
Exclusion Criteria
- One (1) or more osteoporotic vertebral fractures (T4 - L4)
- BMD T-score at the lumbar spine or femoral neck less than -2.5
- Past history or active nontraumatic venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method The percent change from baseline in lumbar spine bone mineral density (BMD) after 6 months of treatment
- Secondary Outcome Measures
Name Time Method Additional BMD evaluation including total hip, femoral neck and trochanter at 6 months Serum bone markers at 3 and 6 months Lipid profile at 3 and 6 months
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie bazedoxifene's effects on bone mineral density in postmenopausal Asian women with osteoporosis?
How does bazedoxifene compare to bisphosphonates in improving bone mineral density in postmenopausal Asian women with osteoporosis?
Which biomarkers correlate with bazedoxifene response in postmenopausal Asian women during Phase 3 trials?
What are the long-term adverse event profiles of bazedoxifene in postmenopausal populations beyond the 6-month NCT00384072 study?
How do SERMs like bazedoxifene compare to estrogen therapy in managing postmenopausal osteoporosis in Asian women?